Newsroom

New technology from Monarch Medical Technologies statistically eliminates severe hypoglycemia in hospital glucose management.

Monarch has achieved a 30 percent growth in total installed sites, an increase in go‐lives by seven times, a five‐fold increase in sales, a second FDA 510(k) clearance for EndoTool SubQ, and a 40 percent increase in new personnel.

EndoTool SubQ utilizes clinically-proven and patent-pending model predictive control technology to determine the safest patient-specific basal/bolus and correction subcutaneous insulin dose recommendations.

The board, which will serve to counsel the company on strategic areas of interest, includes members from both the U.S. and abroad and leverages both healthcare and analytics experts.

Next generation glucose management solution offers several new features to aid healthcare professionals in addressing the most complex cases.

The international quality standard certifies Monarch’s ability to offer medical devices and related services that consistently meet applicable customer needs and regulatory requirements.

Vidant Medical Center, the flagship hospital for Vidant Health and teaching hospital for Brody School of Medicine at East Carolina University, has demonstrated that implementing EndoTool resulted in controlled and sustained improvements in blood sugar levels among patients.

The Monarch name was selected to reflect the company’s mission of transforming the way drugs of concern are dosed and processes of concern are handled in a hospital setting.